@entity15626 effectively inhibits lymphangiogenesis via XXXX induction and G1 cell cycle arrest.

@entity1 @entity1569 @entity5 @entity9104 @entity4269 @entity4910 @entity15626 @entity7596 @entity994
UNASSIGNED: Different pathologies, like @entity4269 , @entity5 or @entity1569 , are associated with abnormal lymphatic vessel formation. Therefore, influencing lymphangiogenesis is an interesting target. Recent evidence suggests that @entity15626 ( @entity9104 ), an anti-psoriatic agent, might have anti-tumorigenic and anti-lymphangiogenic properties. To prove this assumption, we performed proliferation and functional assays with primary @entity1 dermal lymphendothelial cells (DLEC). We could demonstrated that @entity9104 suppresses DLEC proliferation and formation of capillary-like structures. Underlying apoptotic mechanisms could be ruled out. Cell cycle analysis demonstrated a pronounced G1-arrest. Further evaluations revealed increases in @entity994 expression. In addition, @entity9104 suppressed @entity4910 and @entity7596 expression in a concentration dependent manner. @entity994 knockdown experiments demonstrated a @entity994 -dependent mechanism of regulation. Further analysis showed an increased @entity994 mRNA expression after @entity9104 treatment. This transcriptional regulation was enforced by post-transcriptional and post-translational mechanisms. In addition, we could demonstrate, that the combination of a proteasomal inhibitor and @entity9104 superinduced the @entity994 expression. Hence, @entity9104 is a new anti-lymphangiogenic compound and might be used in various illnesses associated with increased lymphangiogenesis. This article is protected by copyright. All rights reserved.
